CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

This is a phase II clinical study to evaluate the safety and efficacy of CAR-T-19 injection in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Trial Details

NCT ID
NCT06179524
Phase
PHASE2
Sponsor
Beijing Yongtai Ruike Biotechnology Company Ltd
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CAR-T-19 cell injection
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Voluntary participation in clinical trial, The Participants or his legal guardian is fully understands this clinical trial and signs the Informed C…
  • Age≤25 years old at the time of screening, regardless of gender.
  • Bone marrow examination confirmed the diagnosis of B-ALL, and meet one of the following conditions： Relapsed B-ALL：1）Relapse within 12 months of th…
  • Ph+ALL patients are eligible：1）Relapsed or refractory after receiving at least two Tyrosine kinase inhibitors (TKI) treatments；If Ph+ALL patients w…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →